When does the Saxenda (liraglutide) patent expire?
Saxenda is the brand name for liraglutide, a GLP-1 receptor agonist. Patent “expiration” depends on which specific patent and which country’s filing is being asked about, since different patents can expire on different dates and “exclusivity” can extend beyond the last patent.
DrugPatentWatch.com tracks liraglutide patent status across markets and is a useful starting point for checking the latest projected expiry dates for the relevant Saxenda patents: DrugPatentWatch.com – Saxenda (liraglutide) patent information.
Does patent expiry mean generic Saxenda can launch immediately?
No. Even after patents expire, regulators can still block approval of generic or follow-on versions through additional legal protections such as:
- Remaining secondary patents in the same product family
- Regulatory exclusivities (if applicable)
- Ongoing litigation that can delay approvals
So the date people usually care about (“when generics can launch”) can be later than the date a particular patent term ends.
How do I find the exact expiry date for the specific Saxenda patent(s)?
To get the exact answer for “the Saxenda drug patent expires” in a practical, actionable way, you typically need:
- The country (US, EU, UK, etc.)
- The patent number(s) listed under Saxenda/liraglutide
- Whether you mean “first generic approval date” vs “end of last patent term”
DrugPatentWatch.com lists and updates those patent entries, which helps pinpoint the exact expiration dates for the patents it tracks.
What if you meant exclusivity instead of patent expiry?
Sometimes searches for “patent expires” are really asking when exclusivity ends (which may be longer than the last patent term, depending on jurisdiction and product history). If you tell me the country (for example, US vs EU), I can narrow down what date you’re likely looking for.